Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) announced on Friday that it has signed a contract with Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ:TLX) for the supply of four Cyclone KIUBE cyclotrons to support its US manufacturing expansion.

The systems will be deployed across selected RLS Radiopharmacies sites in the United States.

This investment is intended to strengthen Telix's supply chain resilience and enable in-house production of therapeutic and diagnostic isotopes for cancer care. It also supports the growth of IBA RadioPharma Solutions and reinforces its market position.

Telix selected the Cyclone KIUBE 180 based on its high-current capacity, industrial reliability, and upgrade potential. Each unit will be integrated with the QUANTM Irradiation System (QIS) developed by ARTMS, a subsidiary of Telix.

The combined technologies will facilitate cGMP-compliant production of isotopes including Gallium-68, Zirconium-89, Technetium-99m, and Copper-64. This integration is expected to enhance localised, high-yield isotope production while reducing reliance on external suppliers and mitigating supply chain risk.